Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers Large healthcare related equities associated with Obamacare. Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
Varian Medical Systems (VAR)
The company has Return on Asset of 5.92 % which means that on every $100 spent on assets, it made $5.92 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 13.51 %, implying that it generated $13.51 on every 100 dollars invested. Varian Medical's management efficiency ratios could be used to measure how well Varian Medical manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a total capitalization of 16.27 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Varian Medical's market, we take the total number of its shares issued and multiply it by Varian Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Wright Medical Group (WMGI)
The company has return on total asset (ROA) of 0.16 % which means that it generated a profit of $0.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.35) %, meaning that it created substantial loss on money invested by shareholders. Wright Medical's management efficiency ratios could be used to measure how well Wright Medical manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 3.9 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Wright Medical's market, we take the total number of its shares issued and multiply it by Wright Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
ICU Medical (ICUI)
The ICU Medical's current Return On Tangible Assets is estimated to increase to -0.01. The current Return On Capital Employed is estimated to decrease to 0.01. As of now, ICU Medical's Total Current Assets are increasing as compared to previous years. The ICU Medical's current Other Current Assets is estimated to increase to about 95.8 M, while Net Tangible Assets are forecasted to increase to (373.7 M). ICU Medical's management efficiency ratios could be used to measure how well ICU Medical manages its routine affairs as well as how well it operates its assets and liabilities. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.35 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ICU Medical's market, we take the total number of its shares issued and multiply it by ICU Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the entity appears to be undervalued. ICU Medical retains a regular Real Value of $122.69 per share. The prevalent price of the entity is $97.76. Our model calculates the value of ICU Medical from analyzing the entity fundamentals such as operating margin of (0.01) %, and Return On Asset of 0.0067 as well as examining its technical indicators and probability of bankruptcy. In general, most investors encourage purchasing undervalued assets and trading away overvalued assets since, at some point future time, asset prices and their ongoing real values will come together.
Align Technology (ALGN)
The company has return on total asset (ROA) of 0.0682 % which means that it generated a profit of $0.0682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1231 %, meaning that it created $0.1231 on every $100 dollars invested by stockholders. Align Technology's management efficiency ratios could be used to measure how well Align Technology manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Align Technology's Return On Tangible Assets are very stable compared to the past year. As of the 23rd of April 2024, Return On Capital Employed is likely to grow to 0.17, while Return On Equity is likely to drop 0.09. At this time, Align Technology's Intangible Assets are very stable compared to the past year. As of the 23rd of April 2024, Net Tangible Assets is likely to grow to about 3.7 B, while Deferred Long Term Asset Charges is likely to drop about 52.9 M. The entity currently falls under 'Large-Cap' category with a current market capitalization of 22.65 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Align Technology's market, we take the total number of its shares issued and multiply it by Align Technology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The firm has a beta of 1.0206. As returns on the market increase, Prestige Brand's returns are expected to increase less than the market. However, during the bear market, the loss of holding Prestige Brand is expected to be smaller as well. The beta indicator helps investors understand whether Prestige Brand moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Prestige deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity currently falls under 'Mid-Cap' category with a total capitalization of 3.47 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Prestige Brand's market, we take the total number of its shares issued and multiply it by Prestige Brand's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the company appears to be undervalued. Prestige Brand Holdings holds a recent Real Value of $77.59 per share. The prevailing price of the company is $71.22. Our model determines the value of Prestige Brand Holdings from analyzing the company fundamentals such as Operating Margin of 0.31 %, return on equity of -0.0491, and Shares Outstanding of 49.65 M as well as examining its technical indicators and probability of bankruptcy. In general, most investors support purchasing undervalued entities and trading away overvalued entities since, at some point, asset prices and their ongoing real values will merge together.
UnitedHealth Group Incorporated (UNH)
The company has Return on Asset of 0.0709 % which means that on every $100 spent on assets, it made $0.0709 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1722 %, implying that it generated $0.1722 on every 100 dollars invested. UnitedHealth Group's management efficiency ratios could be used to measure how well UnitedHealth Group manages its routine affairs as well as how well it operates its assets and liabilities. The UnitedHealth Group's current Return On Equity is estimated to increase to 0.26, while Return On Tangible Assets are projected to decrease to 0.09. As of now, UnitedHealth Group's Total Current Assets are increasing as compared to previous years. The UnitedHealth Group's current Intangible Assets is estimated to increase to about 16 B, while Non Currrent Assets Other are projected to decrease to under 10.9 B. This firm currently falls under 'Mega-Cap' category with a total capitalization of 452.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate UnitedHealth Group's market, we take the total number of its shares issued and multiply it by UnitedHealth Group's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
44.11 Billion
As of now, UnitedHealth Group's Net Debt is increasing as compared to previous years.
Ironwood Pharmaceuticals (IRWD)
The company has return on total asset (ROA) of 0.1339 % which means that it generated a profit of $0.1339 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.7404) %, meaning that it created substantial loss on money invested by shareholders. Ironwood Pharmaceuticals' management efficiency ratios could be used to measure how well Ironwood Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ironwood Pharmaceuticals' Return On Equity is projected to slightly grow based on the last few years of reporting. At present, Ironwood Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 356.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.4 M. The entity currently falls under 'Mid-Cap' category with a current market capitalization of 1.26 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ironwood Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Ironwood Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Ironwood Pharmaceuticals retains a regular Real Value of $9.97 per share. The prevalent price of the firm is $8.31. Our model calculates the value of Ironwood Pharmaceuticals from evaluating the firm fundamentals such as Current Valuation of 1.89 B, return on asset of 0.13, and Return On Equity of -6.74 as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage purchasing undervalued assets and exiting overvalued assets since, at some point, asset prices and their ongoing real values will come together.
HCA Holdings (HCA)
HCA Holdings [HCA] is traded in USA and was established null. HCA Holdings is listed under Health Care Providers & Services category by Fama And French industry classification. The fund is classified under Health Care category within Health Care Providers & Services family. The entity is thematically classified as Healthcare. HCA Holdings currently have 56.21 B in assets under management (AUM). with the current yeild of 0.01%.
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Story appears to be empty
Varian Medical Systems (VAR)
The company has Return on Asset of 5.92 % which means that on every $100 spent on assets, it made $5.92 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 13.51 %, implying that it generated $13.51 on every 100 dollars invested. Varian Medical's management efficiency ratios could be used to measure how well Varian Medical manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a total capitalization of 16.27 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Varian Medical's market, we take the total number of its shares issued and multiply it by Varian Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Wright Medical Group (WMGI)
The company has return on total asset (ROA) of 0.16 % which means that it generated a profit of $0.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.35) %, meaning that it created substantial loss on money invested by shareholders. Wright Medical's management efficiency ratios could be used to measure how well Wright Medical manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 3.9 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Wright Medical's market, we take the total number of its shares issued and multiply it by Wright Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
ICU Medical (ICUI)
The ICU Medical's current Return On Tangible Assets is estimated to increase to -0.01. The current Return On Capital Employed is estimated to decrease to 0.01. As of now, ICU Medical's Total Current Assets are increasing as compared to previous years. The ICU Medical's current Other Current Assets is estimated to increase to about 95.8 M, while Net Tangible Assets are forecasted to increase to (373.7 M). ICU Medical's management efficiency ratios could be used to measure how well ICU Medical manages its routine affairs as well as how well it operates its assets and liabilities. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.35 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ICU Medical's market, we take the total number of its shares issued and multiply it by ICU Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the entity appears to be undervalued. ICU Medical retains a regular Real Value of $122.69 per share. The prevalent price of the entity is $97.76. Our model calculates the value of ICU Medical from analyzing the entity fundamentals such as operating margin of (0.01) %, and Return On Asset of 0.0067 as well as examining its technical indicators and probability of bankruptcy. In general, most investors encourage purchasing undervalued assets and trading away overvalued assets since, at some point future time, asset prices and their ongoing real values will come together.
Align Technology (ALGN)
The company has return on total asset (ROA) of 0.0682 % which means that it generated a profit of $0.0682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1231 %, meaning that it created $0.1231 on every $100 dollars invested by stockholders. Align Technology's management efficiency ratios could be used to measure how well Align Technology manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Align Technology's Return On Tangible Assets are very stable compared to the past year. As of the 23rd of April 2024, Return On Capital Employed is likely to grow to 0.17, while Return On Equity is likely to drop 0.09. At this time, Align Technology's Intangible Assets are very stable compared to the past year. As of the 23rd of April 2024, Net Tangible Assets is likely to grow to about 3.7 B, while Deferred Long Term Asset Charges is likely to drop about 52.9 M. The entity currently falls under 'Large-Cap' category with a current market capitalization of 22.65 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Align Technology's market, we take the total number of its shares issued and multiply it by Align Technology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The firm has a beta of 1.0206. As returns on the market increase, Prestige Brand's returns are expected to increase less than the market. However, during the bear market, the loss of holding Prestige Brand is expected to be smaller as well. The beta indicator helps investors understand whether Prestige Brand moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Prestige deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity currently falls under 'Mid-Cap' category with a total capitalization of 3.47 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Prestige Brand's market, we take the total number of its shares issued and multiply it by Prestige Brand's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the company appears to be undervalued. Prestige Brand Holdings holds a recent Real Value of $77.59 per share. The prevailing price of the company is $71.22. Our model determines the value of Prestige Brand Holdings from analyzing the company fundamentals such as Operating Margin of 0.31 %, return on equity of -0.0491, and Shares Outstanding of 49.65 M as well as examining its technical indicators and probability of bankruptcy. In general, most investors support purchasing undervalued entities and trading away overvalued entities since, at some point, asset prices and their ongoing real values will merge together.
UnitedHealth Group Incorporated (UNH)
The company has Return on Asset of 0.0709 % which means that on every $100 spent on assets, it made $0.0709 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1722 %, implying that it generated $0.1722 on every 100 dollars invested. UnitedHealth Group's management efficiency ratios could be used to measure how well UnitedHealth Group manages its routine affairs as well as how well it operates its assets and liabilities. The UnitedHealth Group's current Return On Equity is estimated to increase to 0.26, while Return On Tangible Assets are projected to decrease to 0.09. As of now, UnitedHealth Group's Total Current Assets are increasing as compared to previous years. The UnitedHealth Group's current Intangible Assets is estimated to increase to about 16 B, while Non Currrent Assets Other are projected to decrease to under 10.9 B. This firm currently falls under 'Mega-Cap' category with a total capitalization of 452.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate UnitedHealth Group's market, we take the total number of its shares issued and multiply it by UnitedHealth Group's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
44.11 Billion
As of now, UnitedHealth Group's Net Debt is increasing as compared to previous years.
Ironwood Pharmaceuticals (IRWD)
The company has return on total asset (ROA) of 0.1339 % which means that it generated a profit of $0.1339 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.7404) %, meaning that it created substantial loss on money invested by shareholders. Ironwood Pharmaceuticals' management efficiency ratios could be used to measure how well Ironwood Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ironwood Pharmaceuticals' Return On Equity is projected to slightly grow based on the last few years of reporting. At present, Ironwood Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 356.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.4 M. The entity currently falls under 'Mid-Cap' category with a current market capitalization of 1.26 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ironwood Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Ironwood Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Ironwood Pharmaceuticals retains a regular Real Value of $9.97 per share. The prevalent price of the firm is $8.31. Our model calculates the value of Ironwood Pharmaceuticals from evaluating the firm fundamentals such as Current Valuation of 1.89 B, return on asset of 0.13, and Return On Equity of -6.74 as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage purchasing undervalued assets and exiting overvalued assets since, at some point, asset prices and their ongoing real values will come together.
HCA Holdings (HCA)
HCA Holdings [HCA] is traded in USA and was established null. HCA Holdings is listed under Health Care Providers & Services category by Fama And French industry classification. The fund is classified under Health Care category within Health Care Providers & Services family. The entity is thematically classified as Healthcare. HCA Holdings currently have 56.21 B in assets under management (AUM). with the current yeild of 0.01%.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Portfolio Suggestion Now
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
